|Videos|February 16, 2016
- Head and Neck Cancers (Issue 4)
- Volume 3
- Issue 4
Dr. Ramona Dadu on Immunotherapies and Their Role in Thyroid Cancer
Author(s)Ramona Dadu, MD
Dadu says immunotherapies could afford patients with thyroid cancer an elongated progression free survival, potentially less toxicities, and most importantly an extensive overall survival benefit.
Advertisement
Ramona Dadu, MD, endocrinologist, MD Anderson Cancer Center, discusses the benefits of using immunotherapies in thyroid cancer and some of the potential drawbacks that coincide with the treatments. Dadu says immunotherapies could afford patients with thyroid cancer an elongated progression free survival, potentially less toxicities, and most importantly an extensive overall survival benefit.
Articles in this issue
over 10 years ago
Immunotherapies Gaining Traction in Head and Neck Cancersover 10 years ago
Dr. Sylvia Asa on Treating Different Types of Thyroid Cancerover 10 years ago
Link Drawn Between Oral HPV and Risk of Head and Neck Cancersover 10 years ago
Nivolumab Could Change Head and Neck Cancer Treatment Paradigmover 10 years ago
Nivolumab Boosts OS in Phase III in SCCHN StudyAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5